What is the clinical evidence, therapeutic purpose, and recommended dosage for N‑acetylcysteine (NAC), glycine, and magnesium glycinate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

N-Acetylcysteine (NAC)

NAC is a proven therapeutic agent with established clinical utility in acetaminophen overdose (where it reduces mortality and hepatotoxicity), and emerging evidence supports its use as an adjunctive treatment in chronic respiratory diseases, aging-related oxidative stress, and select psychiatric conditions.

Clinical Evidence & Therapeutic Purpose

Established Indications

Acetaminophen Overdose (Primary FDA-Approved Use)

  • NAC is the definitive antidote for acetaminophen toxicity, functioning through multiple mechanisms: serving as a sulfhydryl donor for continued nontoxic metabolism, conjugating the toxic metabolite NAPQI, and directly blunting hepatocellular toxicity 1
  • Administer NAC to patients with possible or probable hepatotoxicity risk (as determined by Rumack-Matthew nomogram) ideally within 8-10 hours post-ingestion to reduce severe hepatotoxicity and mortality 1
  • Do NOT administer to patients with no risk per the nomogram 1

Respiratory Diseases

  • NAC demonstrates mucolytic, antioxidant, anti-inflammatory, immunomodulatory, and anti-biofilm properties beyond simple mucus clearance 2
  • In stable COPD (especially chronic bronchitis phenotypes): 600 mg twice daily reduces exacerbation frequency 2
  • High-dose NAC (1200 mg/day) in COPD exacerbations normalizes inflammatory markers (CRP) in 90% of patients versus 19% with placebo, and reduces IL-8 levels more effectively than 600 mg/day 3
  • In influenza prevention: 600 mg twice daily for 6 months reduced symptomatic disease incidence from 79% to 25% in infected individuals, though it did not prevent viral infection itself 4

Aging & Metabolic Health

  • GlyNAC (combined glycine + NAC) supplementation in older adults corrects glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, and multiple aging hallmarks 5
  • This combination improved physical function, insulin resistance, endothelial function, and body composition in a 16-week randomized trial 5

Emerging Psychiatric Applications

  • Adjunctive NAC shows promise in major depressive disorder, bipolar disorder, schizophrenia (particularly negative/cognitive symptoms), OCD, and substance use disorders through glutamatergic modulation and antioxidant mechanisms 6
  • Clinical results remain mixed; larger trials needed to establish definitive protocols 6

Dosing Strategies

Acetaminophen Overdose (FDA-Approved)

Oral Route:

  • Loading dose: 140 mg/kg 7
  • Maintenance dose: 70 mg/kg every 4 hours for 17 additional doses 7
  • For a 100 kg patient: 28 g loading, then 56 g total over 24 hours 8

Intravenous Route:

  • Loading dose: 150 mg/kg over 60 minutes
  • Second dose: 50 mg/kg over 4 hours
  • Third dose: 100 mg/kg over 16 hours
  • For 100 kg patient: 22 g over 8 hours, 30 g over 24 hours 8

Respiratory Conditions

Chronic COPD:

  • 600 mg twice daily (1200 mg/day total) for exacerbation prevention 2

Acute COPD Exacerbations:

  • 1200 mg once daily for 10 days shows superior anti-inflammatory effects compared to 600 mg/day 3

Pediatric Respiratory Disease:

  • 20 mg/kg/day for acute conditions 9
  • 200 mg three times daily for chronic conditions in children >9 years 9
  • Weight-based dosing recommended for children 2-9 years due to significant weight variations 9

Aging & Metabolic Health (GlyNAC Protocol)

  • Glycine + NAC combination: specific dosing from the trial used GlyNAC supplementation (exact glycine:NAC ratio from study: combined supplementation) 5
  • Duration: 16 weeks showed sustained benefits 5

Safety Profile

  • Well-tolerated across all age groups with minimal adverse events 3, 9, 5
  • Oral NAC may cause mild GI upset (nausea, vomiting)
  • IV NAC can cause anaphylactoid reactions (managed by slowing infusion rate)
  • Safe in pregnancy (Category B) though should only be used when clearly needed 7
  • No evidence of carcinogenicity or mutagenicity 7

Critical Caveats

  • Timing is critical in acetaminophen overdose: efficacy dramatically decreases after 10 hours post-ingestion, with hepatotoxicity risk increasing from <2% (if treated <8 hours) to 53% (if treated 10-24 hours) 1
  • NAC should NOT be mixed with other drugs in nebulizers due to unknown stability 7
  • The Rumack-Matthew nomogram only applies to single acute ingestions at known times, not repeated supratherapeutic ingestions or extended-release formulations 1

Glycine

Glycine is an amino acid with limited standalone clinical evidence, but shows significant therapeutic potential when combined with NAC (as GlyNAC) for aging-related conditions and oxidative stress.

Clinical Evidence & Therapeutic Purpose

As Surgical Irrigant (FDA-Approved)

  • 1.5% glycine solution (200 mOsmol/L) is used during transurethral resection procedures as a nonconductive irrigant that minimizes intravascular hemolysis risk 10
  • Rapidly degraded in liver by glycine oxidase; absorbed solution is renally excreted 10

In Combination with NAC (GlyNAC)

  • Glycine + NAC combination corrects glutathione deficiency more effectively than either agent alone 5
  • The combination improved mitochondrial function, reduced oxidative stress, decreased inflammation, and reversed multiple aging hallmarks in older adults 5
  • GlyNAC supplementation for 16 weeks improved gait speed, muscle strength, 6-minute walk distance, and reduced waist circumference 5
  • In spinal cord injury models, GlyNAC (200 mg/kg combined dose) promoted motor and sensory function recovery, protected spinal cord tissue, and delayed skeletal muscle atrophy 11

Dosing

GlyNAC Protocol (Combined with NAC)

  • Combined supplementation for 16 weeks in the landmark aging trial 5
  • 200 mg/kg combined dose in animal models of spinal cord injury 11
  • Specific glycine:NAC ratios vary by study; the combination approach is key to efficacy

Surgical Irrigant

  • 1.5% solution as needed during procedures 10

Safety Profile

  • Glycine is a naturally occurring amino acid with excellent safety profile
  • As part of GlyNAC, well-tolerated for up to 16 weeks with no significant adverse events 5

Magnesium Glycinate

No high-quality clinical evidence was provided in the submitted literature for magnesium glycinate specifically.

General Clinical Context (Based on Medical Knowledge)

Magnesium glycinate is a chelated form of magnesium bound to glycine, offering:

  • Better GI tolerability compared to magnesium oxide or citrate (less diarrhea)
  • Higher bioavailability due to glycine chelation
  • Used for magnesium deficiency, muscle cramps, sleep support, and anxiety

Typical Dosing (General Medical Practice)

  • 200-400 mg elemental magnesium daily (divided doses with meals)
  • For deficiency correction: may require higher doses under medical supervision
  • RDA: 310-420 mg/day depending on age and sex

Safety

  • Generally well-tolerated
  • Contraindicated in severe renal impairment (risk of hypermagnesemia)
  • May interact with bisphosphonates, antibiotics (tetracyclines, quinolones)

Note: The provided evidence does not contain guidelines or high-quality studies specifically addressing magnesium glycinate's clinical applications. The above represents standard clinical practice, but definitive recommendations require consultation of magnesium-specific guidelines.

References

Related Questions

Is N‑acetylcysteine appropriate for treating nasal congestion due to a viral upper‑respiratory infection in an otherwise healthy adult?
What are the indications, dosage, duration, and monitoring recommendations for using N‑acetylcysteine together with acebrophylline in adult patients with acute or chronic bronchopulmonary conditions?
What is the recommended dosage of acetyl cysteine (N-acetylcysteine) for a patient with chronic obstructive pulmonary disease (COPD) or cystic fibrosis requiring mucolysis via nebulizer?
Can an adult patient without known hypersensitivity to N‑acetylcysteine safely take 600 mg orally twice daily for 30 days?
Can N‑acetylcysteine (acetylcysteine) and acebrophylline be used together in an adult without hepatic or renal impairment, and what are the appropriate dosages, duration, and monitoring recommendations?
What are the key differences between the 2026 pediatric guidelines and the 2025 pediatric guidelines?
A patient who is already taking amlodipine (at the maximum dose) has uncontrolled blood pressure; what should be the next step in management?
What patient explanation should be given for the off‑label use of phosphodiesterase‑5 inhibitors (sildenafil or tadalafil) in transgender men who have undergone gender‑affirming surgery or are on testosterone therapy?
For a newly diagnosed hypertensive patient, should I start amlodipine 5 mg daily?
What are the detailed histological features of otosclerosis?
What is the appropriate infectious disease management for a 74-year-old bedridden female with generalized weakness and confusion, normal vital signs and laboratory studies, a moderate left pleural effusion with adjacent atelectatic consolidation on chest CT, no respiratory symptoms, and a positive nasal MRSA polymerase chain reaction colonization?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.